annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 8 Use of meta-analysis of gene expression profiling studies to identify
biologically relevant pathways associated with aggressive breast cancer
(BC) in young women. (Abstract #520)
P. Bedard, R. Salgado, S. K. Singhal, V. Durbecq, M. Ignatiadis, B. Haibe-Kains,
M. Piccart, C. Sotiriou, S. Loi
Brd. 9 Clinically relevant gene signatures in triple-negative and basal-like breast
cancer. (Abstract #521)
A. Rody, T. Karn, C. Liedtke, E. Ruckhäberle, L. Hanker, L. Pusztai, V. Mueller,
M. Schmidt, U. Holtrich, M. Kaufmann
Brd. 10 Correlation of molecular and clinically distinct phenotypes in
HER2-overexpressing breast cancer (HER2� BC) with estrogen receptor
status (ER) status: Implications for anti-HER2 therapy. (Abstract #522)
S. Loi, B. Haibe-Kains, D. N. Brown, J. Metallo, L. X. Huan, C. Desmedt, L. Pusztai,
M. Piccart, F. J. Esteva, C. Sotiriou
Brd. 11 First results from the Patient’s Anastrozole Compliance to Therapy (PACT)
program evaluating the influence of a standardized information service on
compliance in postmenopausal women with early breast cancer (EBC).
(Abstract #523)
N. Harbeck, P. Hadji, C. Jackisch, M. Landthaler, V. Heilmann, B. Baier,
M. Blettner, H. Lück, A. Rexrodt von Fircks, R. Kreienberg
Brd. 12 Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by
postmenopausal women with early-stage breast cancer. (Abstract #524)
J. A. Charlson, T. Hedin, R. Sparapani, C. Guo, A. Nattinger
Brd. 14 Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitorassociated
arthralgia in breast cancer survivors. (Abstract #526)
J. Mao, I. Su, R. Feng, K. Desai, M. Horn, D. Chan, A. DeMichele
Brd. 15 Changes in cognitive function in postmenopausal women 1 year after
completing adjuvant letrozole or tamoxifen in the Breast International Group
(BIG) 1–98 trial. (Abstract #527)
K. Ribi, J. Aldridge, K. Phillips, Z. Sun, A. M. Thompson, V. J. Harvey,
B. Thürlimann, F. Cardoso, A. S. Coates, J. Bernhard
Brd. 16 Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T)
in preserving ovarian function during chemotherapy for early breast cancer
patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella
(GIM) group. (Abstract #528)
L. Del Mastro, L. Boni, A. Michelotti, T. Gamucci, N. Olmeo, M. Giordano, S. Gori,
O. Garrone, C. Bighin, M. Venturini, GIM group
Brd. 18 Pathologic complete response (pCR) in patient subgroups: An analysis of
ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based
neoadjuvant therapy with or without capecitabine in early breast cancer
(EBC). (Abstract #530)
G. G. Steger, R. Greil, R. Jakesz, A. Lang, B. Mlineritsch, M. Rudas, C. Marth,
H. Stoeger, C. F. Singer, M. Gnant, Austrian Breast and Colorectal Cancer Study
Group (ABCSG)
Brd. 19 Integration of capecitabine (X) into adjuvant therapy comprising docetaxel
(T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in
patients with triple-negative breast cancer (BC). (Abstract #531)
H. Joensuu, P. Kellokumpu-Lehtinen, R. Huovinen, A. Jukkola-Vuorinen,
M. Tanner, R. Kokko, J. Ahlgren, P. Bono, P. Auvinen, H. Lindman
Brd. 21 Mature results from ABCSG-12: Adjuvant ovarian suppression combined
with tamoxifen or anastrozole, alone or in combination with zoledronic acid,
in premenopausal women with endocrine-responsive early breast cancer.
(Abstract #533)
M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger,
P. C. Dubsky, R. Jakesz, C. F. Singer, H. Eidtmann, R. Greil
394